Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

The current standard of care for newly diagnosed cases of high-grade glioma is surgical resection followed by RT with concurrent chemotherapy. The most widely used criteria for assessing treatment response are based on a 2D measurement of the enhancing area on MR imaging known as the Macdonald Criteria. Recently, nontumoral increases (pseudoprogression) and decreases (pseudoresponse) in enhancement have been found, and these can confuse outcome evaluation. Here we review pseudoprogression and pseudoresponse and describe how better understanding of these phenomena can aid interpretation.

[1]  P. Wen,et al.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.

[2]  Timothy D Johnson,et al.  Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Mirimanoff,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[4]  T. Cloughesy,et al.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy , 2006, Neurology.

[5]  A. Sahgal,et al.  Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme , 2010, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[6]  A. Alavi,et al.  PET imaging for differentiating recurrent brain tumor from radiation necrosis. , 2005, Radiologic clinics of North America.

[7]  Bart Neyns,et al.  Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. , 2009, Surgical neurology.

[8]  Dieta Brandsma,et al.  Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. , 2008, The Lancet. Oncology.

[9]  P. Wen,et al.  Response criteria for glioma , 2008, Nature Clinical Practice Oncology.

[10]  Dieta Brandsma,et al.  Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide , 2008, Cancer.

[11]  R. Gonzalez,et al.  Clinical and radiographic features of peritumoral infarction following resection of glioblastoma , 2006, Neurology.

[12]  S. Karimi,et al.  Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM) , 2008 .

[13]  B. Drayer,et al.  Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.

[14]  M. J. van den Bent,et al.  Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression , 2004, Neurology.

[15]  P Van Tassel,et al.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. , 2000, Radiology.

[16]  M. J. van den Bent,et al.  Pseudoprogression and pseudoresponse in the treatment of gliomas , 2009, Current opinion in neurology.

[17]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Sundgren MR Spectroscopy in Radiation Injury , 2009, American Journal of Neuroradiology.

[19]  Tracy T Batchelor,et al.  Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.

[20]  R. Jain,et al.  VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer , 2009, Nature Reviews Clinical Oncology.

[21]  A. Brandes,et al.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. , 2008, Neuro-oncology.

[22]  P. Box Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma , 2010 .

[23]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[24]  N. Burnet,et al.  Interpretation of Early Imaging after Concurrent Radiotherapy and Temozolomide for Glioblastoma , 2007 .

[25]  William D Rooney,et al.  Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. , 2011, International journal of radiation oncology, biology, physics.

[26]  P. Wen,et al.  Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression , 2009, Journal of Neuro-Oncology.

[27]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[29]  Dushyant V. Sahani,et al.  Biomarkers of response and resistance to antiangiogenic therapy , 2009, Nature Reviews Clinical Oncology.

[30]  M. Mrugala,et al.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.

[31]  Thomas L Chenevert,et al.  Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. , 2006, Magnetic resonance imaging.

[32]  M. Chamberlain Pseudoprogression in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Susan Chang,et al.  Pseudoprogression and pseudoresponse: Challenges in brain tumor imaging , 2009, Current neurology and neuroscience reports.

[34]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  A. Brandes,et al.  Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.